{"id":722,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"retatrutide-phase-2-obesity-trial-338-adults-48-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/pt-br\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","title":{"rendered":"Ensaio de obesidade da fase Retatrutide 2: 338 adultos durante semanas 48"},"content":{"rendered":"<h2>Por que este estudo \u00e9 frequentemente citado<\/h2>\n<p>Retatrutide foi projetado para ativar os receptores GIP, GLP-1 e glucagon. O artigo 2023 \u00e9 o registro central de varia\u00e7\u00e3o de dose humana revisado por pares para o composto na obesidade, por isso \u00e9 mais \u00fatil do que resumos que mencionam apenas a maior altera\u00e7\u00e3o percentual sem os grupos de dose, resultado do placebo ou observa\u00e7\u00f5es de seguran\u00e7a.<\/p>\n<h2>Como o julgamento foi estruturado<\/h2>\n<p>Os adultos que cumpriram os crit\u00e9rios BMI e de condi\u00e7\u00e3o relacionada com o peso foram randomizados em seis regimes de retatrutida e placebo. A propor\u00e7\u00e3o de aloca\u00e7\u00e3o e os diferentes esquemas de dose inicial fizeram parte do projeto, o que significa que o estudo estava avaliando a resposta \u00e0 dose e a tolerabilidade, bem como os sinais de efic\u00e1cia. O endpoint semana-24 foi prim\u00e1rio; semana 48 foi secund\u00e1rio.<\/p>\n<h2>O que os n\u00fameros significam<\/h2>\n<p>A maior altera\u00e7\u00e3o m\u00e9dia relatada ocorreu no grupo 12 mg, mas a publica\u00e7\u00e3o tamb\u00e9m relatou uma resposta graduada nos grupos 1, 4 e 8 mg e uma compara\u00e7\u00e3o com placebo. Os resultados limite na semana 48 tamb\u00e9m variaram por grupo. Estas s\u00e3o estimativas de ensaios a n\u00edvel de grupo, n\u00e3o uma previs\u00e3o para um indiv\u00edduo e n\u00e3o s\u00e3o provas de que um produto vendido sob o mesmo nome composto seja intercambi\u00e1vel com a interven\u00e7\u00e3o do estudo.<\/p>\n<div class=\"pfm-case-callout\"><strong>Verifica\u00e7\u00e3o de interpreta\u00e7\u00e3o:<\/strong> o valor \u221224.2% frequentemente repetido \u00e9 a m\u00e9dia dos m\u00ednimos quadrados para um grupo randomizado na semana 48. N\u00e3o \u00e9 o resultado para todos os participantes e n\u00e3o foi gerado por um ensaio direto retatrutida versus tirzepatida.<\/div>\n<h2>O que permanece sem solu\u00e7\u00e3o<\/h2>\n<p>O ensaio apoia um sinal humano de Fase 2 e uma discuss\u00e3o dose-resposta. N\u00e3o estabelece manuten\u00e7\u00e3o de longo prazo, eventos adversos raros, efic\u00e1cia comparativa, equival\u00eancia de fabrica\u00e7\u00e3o ou aprova\u00e7\u00e3o regulat\u00f3ria. Essas quest\u00f5es exigem testes posteriores e dados de produtos revisados \u200b\u200bpelos reguladores.<\/p>","protected":false},"excerpt":{"rendered":"<p>Uma leitura rastre\u00e1vel na fonte do estudo randomizado de obesidade da Fase 2, incluindo os resultados do grupo de dose, o padr\u00e3o de eventos adversos e os limites da aplica\u00e7\u00e3o de um registro de interven\u00e7\u00e3o cl\u00ednica ao material de pesquisa.<\/p>","protected":false},"author":0,"featured_media":850,"template":"","class_list":["post-722","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Retatrutide Phase 2 Trial: 338 Adults, 48 Weeks<\/title>\n<meta name=\"description\" content=\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks\" \/>\n<meta property=\"og:description\" content=\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"name\":\"Retatrutide Phase 2 Trial: 338 Adults, 48 Weeks\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teste Retatrutide Fase 2: 338 Adultos, 48 Semanas","description":"Uma leitura rastre\u00e1vel na fonte do estudo randomizado de obesidade da Fase 2, incluindo os resultados do grupo de dose, o padr\u00e3o de eventos adversos e os limites da aplica\u00e7\u00e3o de um registro de interven\u00e7\u00e3o cl\u00ednica ao material de pesquisa.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","og_locale":"pt_BR","og_type":"article","og_title":"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks","og_description":"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.","og_url":"https:\/\/nhdbio.com\/pt-br\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","name":"Teste Retatrutide Fase 2: 338 Adultos, 48 Semanas","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Uma leitura rastre\u00e1vel na fonte do estudo randomizado de obesidade da Fase 2, incluindo os resultados do grupo de dose, o padr\u00e3o de eventos adversos e os limites da aplica\u00e7\u00e3o de um registro de interven\u00e7\u00e3o cl\u00ednica ao material de pesquisa.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study\/722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study\/722\/revisions"}],"predecessor-version":[{"id":727,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/case_study\/722\/revisions\/727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/850"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}